Spiropiperidine indoline-substituted diaryl ureas had been identified as antagonists of the P2Y1 receptor. Enhancements in potency were realized through the introduction of a 7-hydroxyl substitution on the spiropiperidinylindoline chemotype. SAR studies were conducted to improve PK and potency, resulting in the identification of compound 3e, a potent, orally bioavailable P2Y1 antagonist with a suitable
螺
哌啶二氢
吲哚取代的二芳基
脲已被确定为P2Y 1受体的拮抗剂。通过在螺
哌啶基亚胺多林
化学型上引入7-羟基取代来实现效力的增强。进行了
SAR研究以改善PK和效能,从而鉴定出化合物3e,这是一种有效的,口服
生物可利用的P2Y 1拮抗剂,在临床前物种中具有合适的PK分布。在大鼠功效/出血模型中,与P2Y 12拮抗剂
氯吡格雷相比,化合物3e在体内表现出强大的抗血栓形成作用,并改善了出血风险。